Nanoparticles in excipients and their potential impact on patients and pharmaceuticals

Over the past few years, the gastroenterology diagnostic market has witnessed an increase in commercial multiplex diagnostic assays for the detection of a large array of enteric pathogens. These multiplex assays differ in many aspects, one important difference being the number of enteric pathogens that the assays detect. Updated IDSA/SHEA guidelines for the management of infectious diarrhea describe a targeted approach, directing proper test utilization for the diagnosis of infectious diarrhea. The guidelines can assist with the development of targeted testing algorithms to diagnose the enteric pathogens most likely causing disease. This patient-centric targeted testing approach can be supported by using the BD MAX ™ system, which uses separate testing panels for the detection of C. difficile, bacterial, parasitic, and viral pathogens.

Insights from Patient Flows and Patient Journeys are cornerstones to the success of any pharma/medtech product. If the process of insight generation is well done, you will discover more impactful growth

Many orally administered small molecules have low aqueous solubility, which leads to poor oral absorption. For many of these poorly soluble drugs currently in development, amorphous dispersions are increasingly being used as a formulation approach to improve solubility and oral absorption.

While the importance of ligand-receptor binding kinetics on drug action is becoming well established, focus to date has been almost entirely on the role of the dissociation constant on drug efficacy and duration of action.